View More View Less
  • 1 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Klinikai Központ I. Belgyógyászati Klinika, Hetényi Géza Endokrinológiai és Anyagcsere Osztály Pécs Ifjúság út 13. 7624
Restricted access

A tanulmányban renoprotektív szempontból elemzett ONTARGET, ALTITUDE, ACCOMPLISH, ROADMAP és ACCORD-BP vizsgálatokból az a következtetés adódik, hogy bár a microalbuminuria/proteinuria epidemiológiailag erős biomarker, az intervenciós vizsgálatokban sokszor nem megbízható köztes végpont, mert a tényleges vesefunkció ezzel ellentétes viselkedést mutathat. Így bizonyos olyan kezelési módok, amelyek javítják a microalbuminuriát/proteinuriát, a kontrollokhoz képest rendre szignifikánsan rontják a vesefunkciót. Elképzelhető, hogy olyan eljárások esetében, mint a vérnyomáscsökkentés, illetve a renin-angiotenzin rendszerblokád mértéke, a nefroprotekció viszonylatában is létezik egy J-görbére emlékeztető optimumpont. Orv. Hetil., 2013, 154, 243–247.

  • Perk, J., De Backer, G., Gohlk, H., et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J., 2012, 33, 1635–1701.

    Gohlk H. , 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) ' (2012 ) 33 Eur. Heart J. : 1635 -1701.

    • Search Google Scholar
  • Mátyus, J., Nagy, J., Kiss, I., et al.: Cardiovascular risk is increased in all stages of chronic renal disease depending on degree of deterioration of renal function and proteinuria. [Cardiovascularis kockázat az idült vesebetegség minden stádiumában fokozott, a vesefunkció romlásától és a fehérjevizelés mértékétől függően.] Metabolizmus, 2012, 10 (Suppl.), A53–A56. [Hungarian]

    Kiss I. , 'Cardiovascular risk is increased in all stages of chronic renal disease depending on degree of deterioration of renal function and proteinuria. [Cardiovascularis kockázat az idült vesebetegség minden stádiumában fokozott, a vesefunkció romlásától és a fehérjevizelés mértékétől függően.] ' (2012 ) 10 Metabolizmus : A53 -A56.

    • Search Google Scholar
  • Jafar, T. H., Stark, P. C., Schmid, C. H., et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med., 2003, 139, 244–252.

    Schmid C. H. , 'Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis ' (2003 ) 139 Ann. Intern. Med. : 244 -252.

    • Search Google Scholar
  • Mátyus, J., Kiss, I.: Statement on the use of angiotensin converting enzyme inhibitors and angiotensin receptor blocking agents (inhibitors of the renin-angiotensin system) in chronic renal disease. [Állásfoglalás az angiotenzinkonvertálóenzim-gátlók és angiotenzinreceptor-blokkolók idült vesebetegségben történő alkalmazásával (a renin-angiotenzin rendszer gátlásával) kapcsolatban.] Hypertonia és Nephrologia, 2012, 16, 73–74. [Hungarian]

    Kiss I. , 'Statement on the use of angiotensin converting enzyme inhibitors and angiotensin receptor blocking agents (inhibitors of the renin-angiotensin system) in chronic renal disease. [Állásfoglalás az angiotenzinkonvertálóenzim-gátlók és angiotenzinreceptor-blokkolók idült vesebetegségben történő alkalmazásával (a renin-angiotenzin rendszer gátlásával) kapcsolatban.] ' (2012 ) 16 Hypertonia és Nephrologia : 73 -74.

    • Search Google Scholar
  • Nakao, N., Yoshimura, A., Morita, H., et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet, 2003, 361, 117–124.

    Morita H. , 'Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial ' (2003 ) 361 Lancet : 117 -124.

    • Search Google Scholar
  • Kunz, R., Wolbers, M., Glass, T., et al.: The COOPERATE trial: a letter of concern. Lancet, 2008, 371, 1575–1576.

    Glass T. , 'The COOPERATE trial: a letter of concern ' (2008 ) 371 Lancet : 1575 -1576.

  • The Editors of The Lancet: Retraction–Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet, 2009, 374, 1226.

    'Retraction–Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial ' (2009 ) 374 Lancet : 1226 -.

    • Search Google Scholar
  • ONTARGET Investigators, Yusuf, S., Teo, K. K., Pogue, J., et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med., 2008, 358, 1547–1559.

    Pogue J. , 'Telmisartan, ramipril, or both in patients at high risk for vascular events ' (2008 ) 358 N. Engl. J. Med. : 1547 -1559.

    • Search Google Scholar
  • Mann, J. F., Schmieder, R. E., McQueen, M., et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet, 2008, 372, 547–553.

    McQueen M. , 'Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial ' (2008 ) 372 Lancet : 547 -553.

    • Search Google Scholar
  • Barnett, A. H., Bain, S. C., Bouter, P., et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med., 2004, 351, 1952–1961.

    Bouter P. , 'Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy ' (2004 ) 351 N. Engl. J. Med. : 1952 -1961.

    • Search Google Scholar
  • Haynes, R., Mason, P., Rahimi, K., et al.: Dual blockade of the renin-angiotensin system: are two better than one? Nephrol.; Dial. Transplant., 2009, 24, 3602–3607.

    Rahimi K. , 'Dual blockade of the renin-angiotensin system: are two better than one? ' (2009 ) 24 Nephrol.; Dial. Transplant. : 3602 -3607.

    • Search Google Scholar
  • Tobe, S. W., Clase, C. M., Gao, P., et al.: Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation, 2011, 123, 1098–1107.

    Gao P. , 'Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies ' (2011 ) 123 Circulation : 1098 -1107.

    • Search Google Scholar
  • Appel, L. J., Wright, J. T. Jr., Greene, T., et al.: Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med., 2010, 363, 918–929.

    Greene T. , 'Intensive blood-pressure control in hypertensive chronic kidney disease ' (2010 ) 363 N. Engl. J. Med. : 918 -929.

    • Search Google Scholar
  • Parving, H. H., Brenner, B. M., McMurray, J. J., et al.: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med., 2012, 367, 2204–2213.

    McMurray J. J. , 'Cardiorenal end points in a trial of aliskiren for type 2 diabetes ' (2012 ) 367 N. Engl. J. Med. : 2204 -2213.

    • Search Google Scholar
  • Bakris, G. L., Sarafidis, P. A., Weir, M. R., et al., for the ACCOMPLISH Trial investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, 2010, 375, 1173–1181.

    Weir M. R. , 'Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial ' (2010 ) 375 Lancet : 1173 -1181.

    • Search Google Scholar
  • Sarafidis, P. A., Bakris, G., Weber, M., et al.: Changes in glomerular filtration rate with benazepril plus amlodipine or benazepril plus hydrochlorothiazide treatment in hypertensive patients at high risk; an analysis of the ACCOMPLISH trial. World Congress of Nephrology, Milan, Italy; May 23, 2009: Sa199 (abstr). http://www.abstracts2view.com/wcn/view.php?nu=WCN09L_455 (accessed Jan 7, 2010)

  • Zanchetti, A., Grassi, G., Mancia, G.: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens., 2009, 27, 923–934.

    Mancia G. , 'When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal ' (2009 ) 27 J. Hypertens. : 923 -934.

    • Search Google Scholar
  • Ernst, M. E., Carter, B. L., Goerdt, C. J., et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension, 2006, 47, 352–358.

    Goerdt C. J. , 'Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure ' (2006 ) 47 Hypertension : 352 -358.

    • Search Google Scholar
  • Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851–860.

    Clarke W. R. , 'Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes ' (2001 ) 345 N. Engl. J. Med. : 851 -860.

    • Search Google Scholar
  • Haller, H., Ito, S., Izzo, J. L. Jr., et al.: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N. Engl. J. Med., 2011, 364, 907–917.

    Izzo J. L. , 'Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes ' (2011 ) 364 N. Engl. J. Med. : 907 -917.

    • Search Google Scholar
  • ACCORD Study Group, Cushman, W. C., Evans, G. W., Byington, R. P., et al.: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med., 2010, 362, 1575–1585.

    Byington R. P. , 'Effects of intensive blood-pressure control in type 2 diabetes mellitus ' (2010 ) 362 N. Engl. J. Med. : 1575 -1585.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 3 0 0
Feb 2021 11 0 0
Mar 2021 12 0 0
Apr 2021 3 0 0
May 2021 12 0 0
Jun 2021 1 0 0
Jul 2021 0 0 0